
GSK plc
GSKNYSEHealthcareDrug Manufacturers - General
前收盤價
US$52.41
+US$0.45 · +0.87%
GSK公司概覽
歷史價格可能經過調整並有所延遲。
GoAI 研究快照
簡明呈現最新可用的模型資訊。
GoAI評分
Buy
Favorable setup — positive multi-factor alignment
估值
98
Deep Value
動能
48
Neutral
情緒
54
Mixed
風險韌性
77
Moderate Risk
完整 GoAI 研究
繼續查看更深入的依據、催化因素和風險。
人工智慧產生的上下文僅供參考,並非投資建議。
公司概況
公司網站GSK plc, a global pharmaceutical entity founded in 1715 and headquartered in Brentford, United Kingdom, dedicates its efforts to the research, development, and manufacturing of a wide array of medical solutions. Until May 2022, the company was known as GlaxoSmithKline plc. Its primary objective is to prevent and treat illnesses by producing both vaccines and a comprehensive range of specialty and general medicines for markets across the United Kingdom, the United States, and internationally. The company's operations are organized into two key divisions: Commercial Operations and Total R&D. Its extensive vaccine portfolio includes immunizations against shingles, meningitis, respiratory syncytial virus (RSV), seasonal and pandemic influenza, and polio. Beyond preventative care, GSK provides diverse therapeutic products covering critical areas such as HIV, oncology, respiratory and immunology conditions, and other specialized medical fields. This also encompasses inhaled treatments for chronic respiratory ailments like asthma and chronic obstructive pulmonary disease (COPD), along with antibiotics for various infections. Innovation at GSK is frequently driven by strategic partnerships. Notable collaborations include an agreement with CureVac to advance mRNA-based influenza vaccines, and alliances with Wave Life Sciences and Elsie Biotechnologies focused on developing oligonucleotide platforms. Furthermore, GSK has established two distinct strategic collaborations with Relation to progress therapeutics for fibrotic diseases and osteoarthritis. The company is also engaged in a multi-target strategic alliance aimed at developing pioneering treatments for individuals suffering from Parkinson's disease, and a partnership with Flagship Pioneering to identify novel medicines and vaccines.
- 產業
- Drug Manufacturers - General
- 部門
- Healthcare
- 總部
- GB
- 執行長
- Luke Victor Miels
- 上市以來
- 1980年3月28日
- 僱員
- 66,841
市場位置
日內區間
目前US$52.41,
52週區間
目前US$52.41,
- 開盤價
- US$51.35
- 前收盤價
- US$51.96
- 成交量
- 223.08萬
- 0.56× 平均值
- 平均成交量
- 396.44萬
- 日均成交量
- 市值
- 1050.03億 USD
- 貝塔
- 0.3
- 市場參考 1
- 50天平均值
- US$51.8666
- 高於平均水平+1.05%
- 200天平均值
- US$52.1116
- 高於平均水平+0.57%
財務數據
財務快照
最近十二個月估值與收益率
- 本益比(TTM)
- 15.94×
- 股價淨值比(TTM)
- 4.35×
- 股價營收比(TTM)
- 2.31×
- 股息率
- 3.56%
獲利能力和效率
- 毛利率
- 73.29%
- 營業利益率
- 24.12%
- 淨利潤率
- 14.52%
財務健康
- 負債權益比
- 1.03×
財報歷史與展望
- EPS優於預期率
- 100%
- 優於預期11次、低於預期0次、符合預期0次
- 平均EPS意外幅度
- +12.74%
- 11 類似報告
- 最新每股收益結果
- 1.36
- 預估1.27 · 優於預期7.09%
EPS:實際值與預估值
近期已公布業績
營收:實際值與預估值
近期已公布業績
GSK同業公司
持有GSK的ETF
報告持有此股票曝險的交易所交易基金。
State Street SPDR Portfolio Developed World ex-US ETFSPDW1.28億0.31%419.2億 USD0.03%US$52.02+0.79%
Avantis International Equity ETFAVDE7303.66萬0.39%191.01億 USD0.23%US$94.26+0.87%
Fidelity Enhanced International ETFFENI5869.5萬0.52%109.6億 USD0.28%US$41.72+0.77%
VanEck Pharmaceutical ETFPPH4403.04萬4.17%10.71億 USD0.36%US$116.63+1.35%
First Trust Value Line Dividend Index FundFVD3322.77萬0.40%82.95億 USD0.62%US$50.70+0.06%
GMO International Value ETFGMOI1530.69萬2.40%6.37億 USD0.60%US$41.625+1.35%
Hartford Multifactor Developed Markets (ex-US) ETFRODM1397.14萬0.85%16.51億 USD0.29%US$42.22+0.69%
Avantis International Large Cap Value ETFAVIV1073.49萬0.52%20.94億 USD0.25%US$83.50+0.81%
State Street SPDR Portfolio Developed World ex-US ETFSPDW- 市場價值
- 1.28億
- 重量
- 0.31%
- AUM
- 419.2億 USD
- 費用率
- 0.03%
- 價格 / 1日
- US$52.02+0.79%
Avantis International Equity ETFAVDE- 市場價值
- 7303.66萬
- 重量
- 0.39%
- AUM
- 191.01億 USD
- 費用率
- 0.23%
- 價格 / 1日
- US$94.26+0.87%
Fidelity Enhanced International ETFFENI- 市場價值
- 5869.5萬
- 重量
- 0.52%
- AUM
- 109.6億 USD
- 費用率
- 0.28%
- 價格 / 1日
- US$41.72+0.77%
VanEck Pharmaceutical ETFPPH- 市場價值
- 4403.04萬
- 重量
- 4.17%
- AUM
- 10.71億 USD
- 費用率
- 0.36%
- 價格 / 1日
- US$116.63+1.35%
First Trust Value Line Dividend Index FundFVD- 市場價值
- 3322.77萬
- 重量
- 0.40%
- AUM
- 82.95億 USD
- 費用率
- 0.62%
- 價格 / 1日
- US$50.70+0.06%
GMO International Value ETFGMOI- 市場價值
- 1530.69萬
- 重量
- 2.40%
- AUM
- 6.37億 USD
- 費用率
- 0.60%
- 價格 / 1日
- US$41.625+1.35%
Hartford Multifactor Developed Markets (ex-US) ETFRODM- 市場價值
- 1397.14萬
- 重量
- 0.85%
- AUM
- 16.51億 USD
- 費用率
- 0.29%
- 價格 / 1日
- US$42.22+0.69%
Avantis International Large Cap Value ETFAVIV- 市場價值
- 1073.49萬
- 重量
- 0.52%
- AUM
- 20.94億 USD
- 費用率
- 0.25%
- 價格 / 1日
- US$83.50+0.81%
繼續GoAI的研究
在 GoAI 中研究GSKresearch.disclaimer





